CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 249 enrolled
Drug / intervention
blood samples, urine samples and nasopharyngeal swabsbiological
Likely dose
blood samples, urine samples and nasopharyngeal swabs 5mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05557539
NCT05557539N/ACompleted

Hypothesizing the Genesis of Infectious Diseases and Epidemics Through an Integrated Systems Biology Approach

Cliniques universitaires Saint-Luc- Université Catholique de Louvain·interventional·Posted Sep 28, 2022·Updated Sep 18, 2025

In Brief

A clinical study evaluating blood samples, urine samples and nasopharyngeal swabs for SARS-CoV-2 Infection and Influenza Viral Infections. Completed, enrolled 249 participants across 1 site.

Detailed Summary

In this study, the investigators aim to collect phenotypical and extensive unbiased multimodal biological data, at two different time points, and to integrate them using a systems biology approach. The present project aims at generating a systems biology network that can recapitulate the complexity of processes underlying differential SARS-CoV-2 phenotypic responses through exploitation of clinical -omics data. Identifying key determinants and mechanisms of biological variability responsible for phenotypic differences will lead to a better management of patients through the application of precision medicine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedSep 28, 2022
Enrollment StartFeb 7, 2022
Primary CompletionDec 18, 2024
Study CompletionJun 30, 2025
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 3.8 years ago

Interventions

blood samples, urine samples and nasopharyngeal swabsbiological

The following samples will be collected: First time point : 6 blood sample tubes (5mL EDTA, 5mL heparinized and 7.5mL heparinized, 5mL citrate, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium). Second time point : 5 blood sample tubes (5mL EDTA,5mL heparinized and 7.5mL heparinized, 5mL serum, 5mL Tempus Blood RNA Tube); 1 urine sample (10mL in a sterile collector) and 1 naso-pharyngeal swab (1mL UT medium).